ACSVL4 inhibitors comprise a diverse class of compounds strategically designed to modulate the activity of long-chain acyl-CoA synthetase 4 (ACSVL4), a key enzyme involved in lipid metabolism. Triacsin C, for instance, directly inhibits ACSVL4 by suppressing the activation of long-chain fatty acids and their incorporation into lipids, thereby influencing lipid metabolic pathways. This compound plays a pivotal role in altering the cellular utilization of fatty acids and provides a specific tool for dissecting ACSVL4-related lipid metabolic processes. Additionally, several inhibitors indirectly impact ACSVL4 by targeting cellular pathways associated with lipid metabolism. Thiazovivin, a ROCK inhibitor, modulates Rho-associated protein kinase (ROCK) signaling, potentially influencing ACSVL4 through alterations in cytoskeletal dynamics and cellular processes. Similarly, GW5074, a c-Raf inhibitor, affects the MAPK pathway, indirectly modulating ACSVL4 expression and function through downstream signaling cascades.
Moreover, PF-06409577, Torin 1, and AZD8055 act as mTOR pathway modulators, indirectly influencing ACSVL4 through the regulation of lipid metabolic pathways and downstream signaling cascades. These compounds provide valuable tools for understanding the intricate regulatory networks governing ACSVL4 in the context of lipid metabolism. Sanguinarine, Dorsomorphin, Etomoxir, and Bisindolylmaleimide I exert their effects through diverse mechanisms. Sanguinarine, an alkaloid, inhibits NF-κB signaling, potentially modulating ACSVL4 through pathways associated with inflammation and lipid metabolism. Dorsomorphin, an AMPK inhibitor, influences ACSVL4-related lipid metabolism by altering cellular energy homeostasis. Etomoxir, a CPT1 inhibitor, disrupts fatty acid oxidation, impacting ACSVL4-related lipid metabolism by altering the cellular utilization of fatty acids. Bisindolylmaleimide I, a PKC inhibitor, modulates protein kinase C (PKC) signaling, potentially influencing ACSVL4 expression and function through downstream effects on cellular pathways associated with lipid metabolism. In conclusion, ACSVL4 inhibitors, whether direct or indirect, provide essential tools for unraveling the intricacies of lipid metabolism regulated by ACSVL4. The diverse array of compounds presented here offers researchers the means to selectively modulate ACSVL4 and investigate its role in cellular processes associated with lipid metabolism.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $187.00 $843.00 | 14 | |
Inhibitor of long-chain acyl-CoA synthetases, including ACSVL4. Suppresses fatty acid activation and incorporation into lipids, potentially influencing ACSVL4-related lipid metabolism. | ||||||
Thiazovivin | 1226056-71-8 | sc-361380 sc-361380A | 10 mg 25 mg | $284.00 $634.00 | 15 | |
ROCK inhibitor. Modulates Rho-associated protein kinase (ROCK) signaling, potentially impacting ACSVL4 through alterations in cytoskeletal dynamics and cellular processes. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
c-Raf inhibitor. Affects the MAPK pathway, potentially modulating ACSVL4 expression and function through downstream signaling cascades. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AMP-activated protein kinase (AMPK) activator. Indirectly influences ACSVL4 by modulating cellular energy homeostasis and downstream signaling pathways associated with lipid metabolism. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
AMPK inhibitor. Counteracts AMPK activation, potentially impacting ACSVL4-related lipid metabolism by influencing cellular energy homeostasis and downstream signaling cascades. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
mTOR inhibitor. Modulates the mTOR pathway, potentially impacting ACSVL4 through regulation of lipid metabolic pathways and downstream signaling cascades. | ||||||
Sanguinarium | 2447-54-3 | sc-473396 | 10 mg | $220.00 | ||
Alkaloid with multiple cellular effects, including inhibition of NF-κB signaling. May indirectly modulate ACSVL4 by affecting pathways associated with inflammation and lipid metabolism. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
AMPK inhibitor. Modulates AMPK signaling, potentially impacting ACSVL4-related lipid metabolism through alterations in cellular energy homeostasis and downstream signaling cascades. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
Dual mTORC1/mTORC2 inhibitor. Influences the mTOR pathway, potentially modulating ACSVL4 through regulation of lipid metabolic pathways and downstream signaling cascades. | ||||||
(+)-Etomoxir sodium salt | 828934-41-4 | sc-215009 sc-215009A | 5 mg 25 mg | $151.00 $506.00 | 3 | |
Carnitine palmitoyltransferase 1 (CPT1) inhibitor. Disrupts fatty acid oxidation, potentially impacting ACSVL4-related lipid metabolism by altering the cellular utilization of fatty acids. | ||||||